Is early, deep free light chain response really an adverse prognostic factor?

Blood

Volumn 111, Issue 4, 2008, Pages 2490-2491

  Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; THALIDOMIDE;

CANCER SURVIVAL; DRUG RESPONSE; HUMAN; LETTER; LIGHT CHAIN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 41349097100     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-11-125849     Document Type: Letter

References (1)

1. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827-832.